Evaluation of Five Antischizophrenic Agents Against Toxoplasma gondii in Human Cell Cultures

Goodwin, David G.; Strobl, Jeannine S.; Lindsay, David S.

doi:10.1645/ge-2536.1

Cited by 46 publications

(36 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We categorized Socio-demographic data as age, gender, birthplace, urban or rural dwelling, educational level, socioeconomic status and occupation (Goodwin et al, 2011). Putative risk factors comprised cat contacts, contact with cat feces; meat consumption (pork, beef, goat, sheep, mutton, chicken, or other); degree of meat cooking; consumption of untreated water, unwashed raw vegetables, fruits and contact with soil (gardening or agriculture) (Leweke et al, 2004).…”

Section: Methodsmentioning

confidence: 99%

SEROPREVALENCE OF <i>TOXOPLASMA GONDII</i> AMONG SCHIZOPHRENICS AT HOSPITAL KAJANG

Juanah

Jalaludin

Osman

et al. 2013

American Journal of Infectious Diseases

View full text Add to dashboard Cite

Studies have found a high seroprevalence of T. gondii in schizophrenia patients than controls. This casecontrol study was done to determine the serprevalence of Toxoplasma gondii and to identify its risk factors among schizophrenia patients at Hospital Kajang. Eighty-eight (88) schizophrenia patients and 88 nonpsychiatric controls were examined for the presence of anti-Toxoplasma IgG and IgM antibodies by Enzyme Linked Immunosorbent Assay (ELISA). Questionnaires were used to collect socio-demographic and behavioral data among the respondents. From the results, the seroprevalence of anti-T. gondii IgG antibodies was significantly higher (51.0%) in schizophrenia patients than in controls (30.7%); (OR = 2.01; 95% CI: 2.16-3.01; p = 0.023. There was no significant association between the socio-demographic factors and toxoplasmosis. Beef consumption (p = 0.004, OR = 3.852, CI: 1.550-9.569), pork consumption (p<0.001, OR = 13.089, 95%CI: 4.730-36.219) and risky cat contact (p = 0.047, OR = 4.061, 95% CI: 1.985-16.745), were found to be significantly associated with T. gondii infection. Our results show that there is a relationship between toxoplasmosis and schizophrenia.

show abstract

Section: Methodsmentioning

confidence: 99%

SEROPREVALENCE OF <i>TOXOPLASMA GONDII</i> AMONG SCHIZOPHRENICS AT HOSPITAL KAJANG

Juanah

Jalaludin

Osman

et al. 2013

American Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Studies have even demonstrated that T. gondii antibodies in patients with schizophrenia treated with antipsychotic drugs are intermediate between those of patients never treated and those of control groups, with a significant reduction in those patients undergoing current drug treatment, thereby suggestive that antipsychotic treatment may affect T. gondii infection levels (Leweke et al, 2004). Indeed, antipsychotic drugs used in the treatment of schizophrenia have been observed to inhibit the replication of T. gondii tachyzoites in cell culture (Goodwin et al, 2011;Jones-Brando et al, 2003). Likewise, T. gondiiinfected/exposed rats treated with the same key antipsychotic or mood stabiliser drugs during the tachyzoite replicative stage of infection, in particular that of the dopamine D2 antagonist haloperidol (Webster et al, 2006) (Skallova et al, 2006), did not develop the potentially suicidal feline attraction or other predation-specific altered behavioural profiles displayed by their untreated but infected counterparts, nor was there the same level of parasite establishment within the brains of these drug-treated infected rats relative to their untreated infected counterparts (Webster et al, 2006).…”

Section: Current Evidence For T Gondii Manipulation Of Intermediate mentioning

confidence: 99%

Toxoplasma gondiiinfection, from predation to schizophrenia: can animal behaviour help us understand human behaviour?

Webster

Kaushik

Bristow

et al. 2013

Journal of Experimental Biology

149

110

View full text Add to dashboard Cite

SummaryWe examine the role of the protozoan Toxoplasma gondii as a manipulatory parasite and question what role study of infections in its natural intermediate rodent hosts and other secondary hosts, including humans, may elucidate in terms of the epidemiology, evolution and clinical applications of infection. In particular, we focus on the potential association between T. gondii and schizophrenia. We introduce the novel term ʻT. gondii-rat manipulation-schizophrenia modelʼ and propose how future behavioural research on this model should be performed from a biological, clinical and ethically appropriate perspective.

show abstract

“…Reviewed publication dates were limited to 1 January 1980 to 4 July 2015. A total of 5,222 items were filtered for primary literature evaluating the in vitro or in vivo efficacy of clinically available compounds, excluding publications evaluating any drug with a 50% inhibitory concentration (IC 50 ) that was Ͼ10 M or that was determined solely by the less reliable enzyme-linked immunosorbent assay (ELISA) method (81) and those already listed in Table 1. Treatments for ocular infection were not included, as these have been recently reviewed In vivo lethal challenge(s)…”

mentioning

confidence: 99%

Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity

Neville

Zach

Wang

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

e Toxoplasma gondii is an apicomplexan parasite of humans and other mammals, including livestock and companion animals. While chemotherapeutic regimens, including pyrimethamine and sulfadiazine regimens, ameliorate acute or recrudescent disease such as toxoplasmic encephalitis or ocular toxoplasmosis, these drugs are often toxic to the host. Moreover, no approved options are available to treat infected women who are pregnant. Lastly, no drug regimen has shown the ability to eradicate the chronic stage of infection, which is characterized by chemoresistant intracellular cysts that persist for the life of the host. In an effort to promote additional chemotherapeutic options, we now evaluate clinically available drugs that have shown efficacy in disease models but which lack clinical case reports. Ideally, less-toxic treatments for the acute disease can be identified and developed, with an additional goal of cyst clearance from human and animal hosts.

show abstract

Evaluation of Five Antischizophrenic Agents Against Toxoplasma gondii in Human Cell Cultures

Cited by 46 publications

References 41 publications

SEROPREVALENCE OF <i>TOXOPLASMA GONDII</i> AMONG SCHIZOPHRENICS AT HOSPITAL KAJANG

SEROPREVALENCE OF <i>TOXOPLASMA GONDII</i> AMONG SCHIZOPHRENICS AT HOSPITAL KAJANG

Toxoplasma gondiiinfection, from predation to schizophrenia: can animal behaviour help us understand human behaviour?

Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity

Contact Info

Product

Resources

About